It is widely accepted that the CXCR3-CXCL9/CXCL10 axis has a crucial role in driving the trafficking of CD8+ T cells to tumor sites.27 Moreover, activation of that axis promotes the interaction between tumor-specific T cells and dendritic cells in the TME during anti-PD-1 therapy.28 We, therefore, investigated whether LSP1 controls CD8+ T cell migration in response to CXCL9 and CXCL10. The gene discussed is CXCR3; the disease is neoplasm.